Formulation Of Liposomes As A Drug Carrier For Buparvaquone
| dc.contributor.author | Narianan, Shailaja | |
| dc.date.accessioned | 2017-01-24T06:17:56Z | |
| dc.date.available | 2017-01-24T06:17:56Z | |
| dc.date.issued | 2016-01 | |
| dc.description.abstract | This study was carried out to encapsulate the drug buparvaquone (BPQ) and to study its physiochemical properties and along with its in vitro release study. Initial studies focused on elimination of chloroform as lipid solvent and its substitution with ethanol. Result obtained showed that chloroform can be substituted with ethanol. Two different fabrication methods were used to produce liposomes: 1) the classic Bangham method and 2) ethanol injection method. Preliminary study was conducted to study the parameters that affect the particle size and polydispersity index (PDI). Liposomes were formulated with the addition of stabilizers, cholesterol and alpha-tocopherol. The liposomes were characterized based on physicochemical characteristics to record their effects on size and polydispersity. Two formulations obtained from the ethanol injection method were used for loading of buparvaquone whereby the first formulation with 100mg lecithin and 50mg cholesterol, the second one with 100mg lecithin and 50mg alpha-tocopherol. The study conducted for BPQ loading and BPQ encapsulation eliminated Bangham method liposomes as the stability study showed that the particle size and polydispersity increased to above 0.200 within 6 months whilst ethanol injection particles remained stable over same period of time. The BPQ loaded particles for ethanol injection method were larger in size but did not exceed 200nm. The encapsulation efficiency of liposome formulated with cholesterol and alpha tocopherol showed similar encapsulation percentage. The increase in drug: lipid ratio resulted in lower encapsulation efficiency. The drug release study showed more than 80% of drug was released by 24 hours of study. The findings of this study suggest that production of liposome particles successfully encapsulated the drug buparvaquone. Two formulations were successfully formulated. These formulations can be used for further in vivo studies on Leishmania cells. It has a huge potential to be used for further development in the treatment of leishmaniasis. | en_US |
| dc.identifier.uri | http://hdl.handle.net/123456789/3555 | |
| dc.language.iso | en | en_US |
| dc.publisher | Universiti Sains Malaysia | en_US |
| dc.subject | Drug buparvaquone | en_US |
| dc.title | Formulation Of Liposomes As A Drug Carrier For Buparvaquone | en_US |
| dc.type | Thesis | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: